Brineura Cleared By England's NICE For Ultra-Rare Batten Disease
Executive Summary
NICE has recommended BioMarin’s Brineura for use in the National Health Service in England after a managed access deal and product pricing were agreed between BioMarin and NHS England. Final details of the deal are expected next month.